Enliven Therapeutics files audited FY2022 financials with net loss of $37.7M; pro forma cash from $164.5M financing

Enliven Therapeutics, Inc.

Net loss of $37.7M for year ended Dec 31, 2022 vs $24.7M in 2021; R&D spend rose 51% to $31.0M.
Cash and equivalents of $75.5M at Dec 31, 2022; $164.5M PIPE closed concurrently with merger on Feb 23, 2023.
Pro forma financials reflect reverse recapitalization with Imara Inc.; Enliven is accounting acquirer.
Accumulated deficit of $82.9M; company expects current cash to fund ops for at least 12 months.
Audited balance sheet shows total assets of $83.3M and total liabilities of $10.4M at Dec 31, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.